Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting

On June 4, analysts at Guggenheim reiterated their Buy rating for Neurocrine Biosciences, Inc. (NASDAQ:NBIX), keeping their price target at $165. The update was made following a thorough discussion at an investor lunch with the company’s management.

The performance of Ingrezza, the possible effects of TEVA’s Austedo pricing negotiations under the Inflation Reduction Act (IRA), and the launch trends of Crenessity were among the main topics of interest for investors during the conference. As of this year, management expects revenues to rise from the first to the second quarter and then pick up speed in the second half of the year.

According to Neurocrine Biosciences, Inc. (NASDAQ:NBIX), Crenessity’s debut was proceeding well; in the first quarter of 2025, 413 patient enrollment start forms were registered, with management confident about maintaining this progress. Furthermore, the company assured analysts and investors that data from ongoing Phase III programs in schizophrenia and major depressive disorder should be available by 2027 and 2027–2028, respectively.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

While we acknowledge the potential of NBIX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NBIX and that has 100x upside potential, check out our report about the cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.